Trials / Completed
CompletedNCT02418624
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
A Phase I Followed by a Randomized Phase II Trial of Two Cycles Carboplatin-Olaparib Followed by Olaparib Monotherapy Versus Capecitabine in BRCA-1 or -2 Mutated Her2 Negative Advanced Breast Cancer as First Line Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.
Detailed description
A 3+3 dose escalation trial of 2 cycles (21 days) carboplatin and olaparib combination therapy, followed by olaparib monotherapy until progression or unacceptable toxicity in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | carboplatin, olaparib | 2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy. |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2015-04-16
- Last updated
- 2019-01-16
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02418624. Inclusion in this directory is not an endorsement.